Business ❯ Corporate Strategy ❯ Mergers and Acquisitions ❯ Market Trends

Biotech M&A

JPM 2026 Opens Quietly as Pharma Prioritizes Mid-Sized Deals and Licensing

Falling valuations alongside pricing debates are steering buyers toward targeted acquisitions and partnerships.